Shots:

• The US FDA has approved NDA for Dartisla ODT (glycopyrrolate) to treat adults to reduce symptoms of a peptic ulcer as an adjunct for peptic ulcer. The therapy is supplied as 1.7mg glycopyrrolate ODT & is expected to be available in early 2022 as its first branded specialty prescription product
• Additionally, patients receiving the 2mg dose of another oral tablet form of glycopyrrolate can be switched to the 1.7mg dose of glycopyrrolate ODT
• The therapy is manufactured by Catalent using Zydis ODT delivery technology to produce a freeze-dried tablet that disperses instantly in the mouth without water

Ref: Businesswire | Image: Edenbridge